Mills-Peninsula Health Services

A Focus on STRIVE: Sutter Health Leads its Largest-enrolling Clinical Trial to Date

Posted on Feb 20, 2019 in Alta Bates Summit Medical Center, California Pacific Medical Center, Eden Medical Center, Innovation, Mills-Peninsula Health Services, Novato Community Hospital, Palo Alto Medical Foundation, Research, Scroll Images, Sutter East Bay Medical Foundation, Transformation

SAN FRANCISCO – Several Sutter Health sites participated in STRIVE, a study that is evaluating a new tool for the detection of early-stage breast cancer. Begun in 2017 and now closed to enrollment, the study recruited the highest number of Sutter patients of any trials to date, regardless of therapeutic area.

The multicenter study will evaluate a new blood test potentially complementary to mammography for early detection of breast cancer. The test is being developed by GRAIL, Inc., and the study recruited women at mammography centers across Sutter Health and the Mayo Clinic.

Read More

Racing Against Time, Mobile Stroke Unit Treats First Stroke Patient

Posted on Feb 11, 2019 in Expanding Access, Innovation, Mills-Peninsula Health Services, Scroll Images, Women's Services

The Sutter Health Mobile Stroke Unit team got the call they had been preparing for and raced into action.

Read More

Providing new treatment options to patients with advanced cancers: Sutter participates in innovative TAPUR™ study

Posted on Feb 11, 2019 in Affiliates, Alta Bates Summit Medical Center, California Pacific Medical Center, Eden Medical Center, Innovation, Memorial Hospital, Los Banos, Memorial Medical Center, Mills-Peninsula Health Services, Research, Scroll Images, Sutter Gould Medical Foundation, Sutter Lakeside Hospital, Sutter Maternity and Surgery Center, Santa Cruz, Sutter Medical Foundation, Sutter Roseville Medical Center, Transformation

SAN FRANCISCO – Sutter Health is enrolling patients to the Targeted Agent and Profiling Utilization (TAPUR™) study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs.

 

 

 

 

Read More